ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGIO Agios Pharmaceuticals Inc

34.14
0.60 (1.79%)
15 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agios Pharmaceuticals Inc NASDAQ:AGIO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 1.79% 34.14 33.87 34.53 34.19 33.20 33.55 518,105 01:00:00

Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

16/04/2020 12:00pm

GlobeNewswire Inc.


Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agios Pharmaceuticals Charts.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, April 30, 2020 at 8:00 a.m. ET to report its first quarter 2020 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 1151878. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About AgiosAgios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.

Contacts

Investors:Holly Manning, 617-844-6630Director, Investor RelationsHolly.Manning@agios.com

Media:Jessica Rennekamp, 857-209-3286Associate Director, Corporate CommunicationsJessica.Rennekamp@agios.com

1 Year Agios Pharmaceuticals Chart

1 Year Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock